| Literature DB >> 24058617 |
Steve Hamner1, Kate McInnerney, Kerry Williamson, Michael J Franklin, Timothy E Ford.
Abstract
Bile salts exhibit potent antibacterial properties, acting as detergents to disrupt cell membranes and as DNA-damaging agents. Although bacteria inhabiting the intestinal tract are able to resist bile's antimicrobial effects, relatively little is known about how bile influences virulence of enteric pathogens. Escherichia coli O157:H7 is an important pathogen of humans, capable of causing severe diarrhea and more serious sequelae. In this study, the transcriptome response of E. coli O157:H7 to bile was determined. Bile exposure induced significant changes in mRNA levels of genes related to virulence potential, including a reduction of mRNA for the 41 genes making up the locus of enterocyte effacement (LEE) pathogenicity island. Bile treatment had an unusual effect on mRNA levels for the entire flagella-chemotaxis regulon, resulting in two- to four-fold increases in mRNA levels for genes associated with the flagella hook-basal body structure, but a two-fold decrease for "late" flagella genes associated with the flagella filament, stator motor, and chemotaxis. Bile salts also caused increased mRNA levels for seventeen genes associated with iron scavenging and metabolism, and counteracted the inhibitory effect of the iron chelating agent 2,2'-dipyridyl on growth of E. coli O157:H7. These findings suggest that E. coli O157:H7 may use bile as an environmental signal to adapt to changing conditions associated with the small intestine, including adaptation to an iron-scarce environment.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24058617 PMCID: PMC3769235 DOI: 10.1371/journal.pone.0074647
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Lack of change in mRNA levels for Shiga-like toxin genes in O157:H7 cells treated with 0.8% bile salts relative to control (calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment).
|
|
|
|
|
|---|---|---|---|
|
| Shiga-like toxin 1 - virulence | 1.06 (insignificant) | NS |
|
| " | 1.15 (insignificant) | NS |
|
| Shiga-like toxin 2 - virulence | 1.06 (insignificant) | NS |
|
| " | .90 (insignificant) | NS |
“NS” denotes “not significant” for p-values > 0.05.
Downregulation of Locus of Enterocyte Effacement (LEE) mRNAs in O157:H7 cells treated with 0.8% bile salts relative to control.
|
|
|
|
|
|---|---|---|---|
| Z5100 |
| .36 | .002 |
| Z5102 | - | .38 | .009 |
| Z5103 |
| .30 | < .001 |
| Z5104 |
| .38 | .003 |
| Z5105 |
| .62 | NS |
| Z5106 |
| .56 | NS |
| Z5107 |
| .57 | NS |
| Z5108 |
| .38 | < .001 |
| Z5109 |
| .31 | < .001 |
| Z5110 |
| .43 | .025 |
| Z5111 |
| .38 | .003 |
| Z5112 |
| .45 | < .001 |
| Z5113 |
| .31 | < .001 |
| Z5114 |
| .27 | < .001 |
| Z5115 |
| .44 | .002 |
| Z5116 |
| .19 | < .001 |
| Z5117 | - | .25 | < .001 |
| Z5118 | - | .29 | < .001 |
| Z5119 |
| .26 | < .001 |
| Z5120 |
| .34 | < .001 |
| Z5121 | - | .30 | < .001 |
| Z5122 |
| .30 | < .001 |
| Z5123 | - | .18 | < .001 |
| Z5124 |
| .16 | < .001 |
| Z5125 |
| .22 | < .001 |
| Z5126 |
| .20 | < .001 |
| Z5127 |
| .14 | < .001 |
| Z5128 |
| .28 | < .001 |
| Z5129 |
| .33 | < .001 |
| Z5131 | - | .50 | < .001 |
| Z5132 |
| .15 | < .001 |
| Z5133 |
| .15 | < .001 |
| Z5134 |
| .26 | < .001 |
| Z5135 |
| .26 | < .001 |
| Z5136 | - | .17 | < .001 |
| Z5137 | - | .26 | < .001 |
| Z5138 |
| .27 | < .001 |
| Z5139 | - | .33 | < .001 |
| Z5140 |
| .39 | < .001 |
| Z5142 |
| .47 | < .001 |
| Z5143 | - | .55 | .007 |
Calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment.
“NS” denotes “not significant” for p-values > 0.05.
Changes in mRNA levels measured using quantitative RT-PCR vs. microarray in O157:H7 cells treated with 0.8% bile salts relative to control.
|
|
|
|
|---|---|---|
|
| .56 | .43 |
|
| .50 | .26 |
|
| .42 | .20 |
|
| .52 | .39 |
|
| .12 | .14 |
|
| 2.08 | 2.01 |
|
| 2.00 | 1.89 |
|
| .51 | .30 |
Calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment. The same RNA preparations (three independent preparations for each treatment) were used for RT-PCR as were used for the microarrays.
Upregulation of mRNA levels for Class 2, or “middle” flagellar genes encoding hook-basal body structures in O157:H7 cells treated with 0.8% bile salts relative to control.
|
|
|
|
|
|---|---|---|---|
| Class 1 (early) genes – | |||
|
| transcriptional activator-flagellar class 2 operons | 0.84 | NS |
|
| transcriptional activator-flagellar class 2 operons | 0.83 | NS |
| Class 2 (middle) genes – | |||
|
| flagellar basal body-associated protein | 2.53 | .006 |
|
| flagellar motor switching & energizing | 3.22 | .004 |
|
| flagellar switch protein | 3.48 | .004 |
|
| flagellar biosynthesis protein | 3.46 | .007 |
|
| flagellar biosynthesis protein | 3.54 | .010 |
|
| flagellar biosynthesis protein | 3.91 | .010 |
|
| flagellar biosynthesis; export pore protein | 2.99 | .031 |
| Class 2 (middle) genes – | |||
|
| flagellar hook-basal body protein | 2.62 | .009 |
|
| flagellar basal body MS-ring and collar protein | 3.12 | .004 |
|
| flagellar motor switch protein | 4.79 | .002 |
|
| flagellar biosynthesis protein | 3.42 | .002 |
|
| flagellum-specific ATP synthase | 3.27 | .008 |
|
| flagellar biosynthesis chaperone | 2.46 | .024 |
|
| flagellar hook-length control protein | 2.57 | .009 |
| Class 2 (middle) genes – | |||
|
| flagellar basal body P-ring biosynthesis protein | 4.25 | < .001 |
|
| anti-FliA (anti-sigma 28) factor; FlhD regulator | 0.89 | NS |
|
| initiation of flagellar filament assembly | 0.80 | NS |
| Class 2 (middle) genes – | |||
|
| flagellar basal body rod protein | 4.47 | < .001 |
|
| flagellar basal body rod protein | 2.78 | < .001 |
|
| flagellar hook assembly protein | 3.46 | .002 |
|
| flagellar hook protein | 3.07 | .001 |
|
| flagellar basal body rod protein | 2.68 | .002 |
|
| flagellar basal body rod protein | 2.64 | .002 |
|
| flagellar synthesis, basal body L ring lipoprotein | 3.29 | .004 |
|
| flagellar basal body P-ring protein | 1.94 | .019 |
|
| flagellar rod assembly protein/muramidase | 2.04 | .020 |
| Class 2 (middle) genes – | |||
|
| flagellar biosynthesis protein | 1.67 | .045 |
|
| flagellar biosynthesis protein | 2.30 | .006 |
|
| flagellar protein | 4.27 | .003 |
| Class 2 (middle) genes – | |||
|
| Alternative sigma factor 28 | 1.02 | NS |
|
| RpoS antagonist | 0.99 | NS |
|
| Possible regulator of FliA | 0.98 | NS |
Calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment.
“NS” denotes “not significant” for p-values > 0.05.
Downregulation of mRNA levels for “late” flagellar genes (flagellar filament, motor stator, and coregulated chemotaxis genes) in O157:H7 cells treated with 0.8% bile salts relative to control.
|
|
|
|
|
|---|---|---|---|
| Class 2/Class 3 (middle & late) genes - | |||
|
| flagellar capping protein | .47 | < .001 |
|
| flagellar protein, potentiates polymerization | .47 | < .001 |
|
| flagellar biosynthesis protein | .43 | < .001 |
| Class 2/Class 3 (middle & late) genes – | |||
|
| flagellar hook-filament junction protein | .63 | .024 |
|
| flagellar hook-filament junction protein | .53 | < .001 |
| Class 3 (late) gene – | |||
|
| Flagellin | .53 | < .001 |
| Class 3 (late) genes – | |||
|
| methyl-accepting chemotaxis protein; sensor | .51 | < .001 |
|
| chemotaxis for dipeptides & pyrimidines | .45 | < .001 |
|
| chemotaxis regulator, methyltransferase | .44 | < .001 |
|
| chemotaxis-specific methylesterase | .48 | < .001 |
|
| chemotaxis regulator, signaling to flagellar motor | .57 | .001 |
|
| chemotaxis regulator, protein phosphatase for CheY | .55 | < .001 |
| Class 3 (late) genes – | |||
|
| stator, proton conductor component of flagella motor | .51 | < .001 |
|
| stator, protein that enables flagellar motor rotation | .49 | < .001 |
|
| chemotaxis response regulator | .41 | < .001 |
|
| purine-binding chemotaxis protein | .45 | < .001 |
| Class 3 (late) genes - | |||
|
| Methyl-accepting chemotaxis protein, serine sensor | .40 | < .001 |
|
| aerotaxis sensor receptor, flavoprotein | .27 | < .001 |
Calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment.
Changes in mRNA levels for genes related to membrane permeability and drug efflux in O157:H7 cells treated with 0.8% bile salts relative to control.
|
|
|
|
|
|---|---|---|---|
|
| Outer membrane protein C porin - permeability | 0.97 | NS |
|
| Outer membrane protein F porin - permeability | 0.14 | < .001 |
|
| Anti-sense RNA - negative regulation of OmpF translation | 2.27 | < .001 |
|
| Multiple antibiotic resistance (mar) protein A - transcription activator of mar regulon | 2.01 | < .001 |
|
| mar protein B | 2.22 | < .001 |
|
| mar operon repressor | 1.80 | .003 |
|
| Regulatory protein SoxS - superoxide response regulon | 0.37 | < .001 |
|
| Acriflavine resistance protein A - antibiotic and bile resistance | 1.89 | < .001 |
|
| Acriflavine resistance protein B - antibiotic and bile resistance | 2.21 | < .001 |
|
| Acriflavine resistance protein R –transcription regulator | 2.83 | < .001 |
|
| Multidrug resistance protein - antibiotic and bile resistance | 2.04 | .002 |
|
| Drug (microcin) efflux pump | 2.49 | < .001 |
Calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment.
“NS” denotes “not significant” for p-values > 0.05.
Changes in mRNA levels for genes related to adhesion in O157:H7 cells treated with 0.8% bile salts relative to control.
|
|
|
|
|
|---|---|---|---|
|
| Outer membrane protein A porin - cell shape/integrity, adhesion | 1.23 | NS |
|
| tdc operon transcription activator - negative regulation of ompA | 0.30 | < .001 |
|
| lysine decarboxylase | 0.17 | < .001 |
|
| cadaverine/lysine antiporter | 0.17 | < .001 |
|
| major F9 fimbrial subunit | 1.40 | .012 |
|
| F9 fimbriae - predicted adhesin | 2.23 | .005 |
|
| F9 fimbriae - predicted adhesin | 2.25 | .027 |
|
| Cadmium binding protein, implicated in adhesion | 1.92 | .004 |
Calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment.
“NS” denotes “not significant” for p-values > 0.05.
Iron acquisition genes upregulated in O157:H7 cells treated with 0.8% bile salts relative to control.
|
|
|
|
|
|---|---|---|---|
|
| Iron transport | 2.76 | < .001 |
|
| TonB accessory protein | 2.42 | < .001 |
|
| TonB accessory protein | 2.85 | < .001 |
|
| Ferrichrome (siderophore) uptake | 5.40 | < .001 |
|
| Ferrichrome (siderophore) uptake | 2.70 | < .001 |
|
| Ferrichrome (siderophore) uptake | 1.76 | .001 |
|
| Ferric iron reductase | 2.44 | < .001 |
|
| Ferrous iron acquisition | 2.88 | < .001 |
|
| Ferrous iron acquisition | 2.57 | < .001 |
|
| DNA-binding, transcription regulator | 2.81 | < .001 |
|
| Ferric enterobactin transport | 4.18 | < .001 |
|
| Ferric enterobactin transport | 2.78 | < .001 |
|
| ATP-binding component, ferric enterobactin transport | 2.88 | < .001 |
|
| Enterobactin (siderophore) synthesis | 1.60 | .006 |
|
| Bacterioferritin-associated ferredoxin | 1.84 | .004 |
|
| Putative outer membrane receptor for iron compound (hemin) or colicin | 1.95 | .004 |
| Z4383 | Putative iron ABC transporter permease | 1.61 | .018 |
Calculations of “fold change” are based on triplicate culture/microarray experiments for each treatment.
Figure 1Growth of O157:H7 in LB medium, with and without 250 µM 2,2’-dipyridyl (DPD), with and without 0.8% bile salts.
Four independent growth curve experiments were conducted and showed similar results. Linear and semi-log growth curve plots of OD600 over 20 hours for one of these experiments are presented in this figure. Error bars represent standard deviations for triplicate platings.
Figure 2Effects of treatment with 250 µM 2,2’-dipyridyl (DPD) and/or 0.8% bile salts on exponential growth of O157:H7 in LB medium.
Four independent growth curve experiments were conducted and showed similar results. Expanded linear and semi-log plots of OD600 for the first 3 hours 15 minutes of growth are provided for the same experimental data presented in Figure 1. Error bars represent standard deviations for triplicate platings.
Calculations of log growth phase doubling times for O157:H7 H7 grown in LB medium, with and without 250 µM 2,2’-dipyridyl (DPD), with and without 0.8% bile salts.
|
| ||||
|---|---|---|---|---|
|
|
|
|
|
|
| 1st | 24.5 | 30.7 | 27.4 | 28.0 |
| 2nd | 23.5 | 32.1 | 23.0 | 28.1 |
| 3rd | 22.9 | 33.2 | 22.4 | 25.9 |
| 4th | 23.2 | 31.9 | 23.0 | 26.7 |
| Mean doubling time, four experiments (+/- standard error of mean) | 23.5 (+/- 0.3) | 32.0 (+/- 0.5) | 24.0 (+/- 1.2) | 27.2 (+/- 0.5) |
Four independent growth curve experiments were conducted. Calculations of doubling times were made for the time interval 30 to 90 minutes (inclusive) when exponential growth curves (see Figure 2) were steepest.